Peptide profile · Immune
Daptomycin
Cyclic lipodepsipeptide antibiotic containing 13 amino acids and a decanoyl lipid tail from Streptomyces roseosporus — FDA-approved as Cubicin for complicated skin infections (2003) and S. aureus bacteremia including right-sided endocarditis (2006), operating through calcium-dependent phosphatidylglycerol-specific membrane depolarization with rapid bactericidal activity against MRSA, VRE, and other multidrug-resistant Gram-positive pathogens
Written & reviewed by Michael Carroll · Research, Peptide Initiative
Typical dose
6 mg/kg
Half-life
Terminal half-life: 8-9 hours in healthy adults with normal renal function; supports once-daily dosing; post-antibiotic effect: 1-6 hours against S. aureus; renal dose adjustment: CrCl <30 mL/min — extend interval to every 48 hours
Bioavailability
IV: 100% (direct administration); not orally bioavailable (degraded in GI tract); inactivated in lungs by pulmonary surfactant
Molecular weight
1,620.69 Da
Evidence level
Strong human trials
01 · Compound profile
Scientific & efficacy data
Molecular formula
C₇₂H₁₀₁N₁₇O₂₆
Primary benefits
Kills dangerous bacteria that have become resistant to other antibiotics, including MRSA and VRE that don't respond to older treatments.
FDA-approved to treat serious blood infections and heart valve infections caused by staph bacteria, with faster clearing than older options.
FDA-approved for complicated skin infections including surgical wounds and diabetic foot infections that need strong antibiotic coverage.
Cubist Pharmaceuticals (Merck)
Amino acid sequence
Decanoyl-LTPIKDVGRLLTGYVDGGQQVLTGS02 · Dosing
How much do I take?
6 mg/kg · once every 24 hours
Intravenous: Delivered straight into a vein through a drip (IV), done by a clinician.
Bioavailability Complete (about 100%) — delivered straight into the bloodstream.
Best time to take
Daptomycin is administered intravenously in a clinical setting. Timing is determined by your healthcare provider based on the treatment protocol and your medical needs.
With food?
IV administration of Daptomycin is not dependent on meal timing. Your healthcare team will provide specific instructions regarding food and fluid intake around treatment sessions.
If stacking
Daptomycin should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
＋ Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
－ Decrease if
- −Side effects are bothersome or impacting daily life despite management strategies
- −You experience any signs of an adverse reaction
- −Lab results indicate the need for dose reduction
- −Your healthcare provider recommends a lower dose based on your response
✓ Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Select Weight
Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)
03 · Suitability
Is this right for me?
Best for treatment of mrsa bacteremia and right-sided infective endocarditis (fda-approved indication at 6 mg/kg) & complicated skin and skin structure infections including surgical site infections and diabetic foot infections (fda-approved at 4 mg/kg)
Best for
Treatment of MRSA bacteremia and right-sided infective endocarditis (FDA-approved indication at 6 mg/kg)
Daptomycin is particularly well-suited for individuals focused on treatment of mrsa bacteremia and right-sided infective endocarditis (fda-approved indication at 6 mg/kg). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Complicated skin and skin structure infections including surgical site infections and diabetic foot infections (FDA-approved at 4 mg/kg)
Daptomycin is particularly well-suited for individuals focused on complicated skin and skin structure infections including surgical site infections and diabetic foot infections (fda-approved at 4 mg/kg). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
VRE bloodstream infections and endocarditis when ampicillin-based therapy is not feasible
Daptomycin is particularly well-suited for individuals focused on vre bloodstream infections and endocarditis when ampicillin-based therapy is not feasible. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Outpatient parenteral antibiotic therapy (OPAT) for Gram-positive infections requiring IV treatment
Daptomycin is particularly well-suited for individuals focused on outpatient parenteral antibiotic therapy (opat) for gram-positive infections requiring iv treatment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Daptomycin with similar peptides to find the best fit for your goals.
04 · Administration
How do I use it?
Intravenous infusion over 30 minutes (FDA-approved) · Intravenous push over 2 minutes (FDA-approved alternative)
Reconstitution — what you need
Example
Add the recommended volume of bacteriostatic water to the Daptomycin vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of Daptomycin is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Technique
- 01Wash your hands thoroughly with soap and water before handling supplies
- 02Clean the injection site with an alcohol swab and let it air dry completely
- 03Pinch a fold of skin at the chosen injection site
- 04Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
- 05Inject the medication slowly and steadily over 5-10 seconds
- 06Release the skin fold and remove the needle, applying gentle pressure with a clean swab
- 07Rotate injection sites to prevent tissue irritation or lipodystrophy
- 08Dispose of the needle safely in a sharps container—never recap or reuse needles
Storage · before reconstitution
Store Daptomycin in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Storage · after reconstitution
Once reconstituted, Daptomycin should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation
Sample daily schedule
05 · Safety
Is it safe?
4 common side effects · 2 serious
Daptomycin is an FDA-approved antibiotic with extensive clinical safety data from Phase 2/3 trials and post-market pharmacovigilance spanning over 20 years. Key safety concerns include muscle toxicity (creatine phosphokinase elevation) occurring in 3-12% of treated patients, potentially progressing to myopathy with weakness if unmonitored. Pulmonary toxicity (eosinophilic pneumonia) is rare (<1%) but serious. Peripheral neuropathy, nausea, and injection site reactions are common but usually mild. Creatinine elevation in renal impairment is significant—dosing must be reduced in patients with eGFR <30 mL/min. CPK monitoring is essential during treatment, especially in patients on statins or with baseline elevations.
Daptomycin was studied through Phase 2 and Phase 3 clinical trials for bacterial infections including bacteremia and endocarditis, with FDA approval based on large multicenter randomized controlled trials. Post-marketing surveillance data spans 20+ years of widespread clinical use. Adverse event monitoring is well-established, and risk factors for myopathy and pulmonary toxicity are well-characterized.
Common side effects · experienced by some users
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Daptomycin
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Daptomycin should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- ✓Beta-lactams (nafcillin, ceftaroline — 'seesaw effect' synergy: beta-lactam resistance in MRSA is associated with increased daptomycin susceptibility; ceftaroline + daptomycin combination therapy for persistent MRSA bacteremia) — May be used together under medical guidance.
- ✓Rifampicin (synergistic biofilm penetration — rifampicin inhibits RNA synthesis in biofilm-embedded bacteria while daptomycin provides rapid bactericidal membrane activity) — May be used together under medical guidance.
- ✓Trimethoprim-sulfamethoxazole (complementary mechanisms for VRE and complex Gram-positive infections; oral TMP-SMX enables step-down from IV daptomycin) — May be used together under medical guidance.
With medications
- !Statins (HMG-CoA reductase inhibitors) — additive myotoxicity risk with daptomycin; consider temporary statin discontinuation during daptomycin therapy or monitor CPK more frequently — Use with caution—discuss with your healthcare provider.
- !Tobramycin (in vitro antagonism demonstrated when co-administered with daptomycin for certain organisms — potential reduced efficacy) — Use with caution—discuss with your healthcare provider.
- !Use for pneumonia or respiratory infections — daptomycin is inactivated by pulmonary surfactant; this is an absolute clinical restriction, not a drug interaction — Use with caution—discuss with your healthcare provider.
With supplements
- ✓Multivitamins — Generally safe to take alongside Daptomycin. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
06 · Effectiveness
How do I know it's working?
Strong human trials · first signs hours 0-48 (initiation)
Evidence level
Strong human trials
(Phase 3 or FDA approved)
How it works
Daptomycin is a lipopeptide antibiotic that kills dangerous bacteria like MRSA by disrupting their cell membranes, making it crucial for treating serious skin, heart, and bloodstream infections.
Daptomycin is a 13-amino acid cyclic lipopeptide containing an unusual β-methyl group at the N-terminus and an N-decanoyl fatty acid modification that anchors the peptide into bacterial cell membranes. Upon calcium-dependent conformational changes and oligomerization on the membrane surface, daptomycin forms membrane-disrupting pores through an α-helical intermediate state, causing rapid depolarization of the bacterial membrane potential, efflux of potassium ions, and loss of cellular contents leading to bactericidal activity. Its mechanism is unique among antibiotics and provides activity against Gram-positive bacteria including vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA).
What to expect
Hours 0-48 (initiation)
What you might notice
- •IV infusion generally well-tolerated; mild injection site discomfort possible
- •Bactericidal activity begins within hours of achieving therapeutic levels
- •Baseline CPK obtained for monitoring
- •Nausea or headache may occur with first doses
What's normal
- •Daptomycin achieves peak bactericidal activity within the first 24 hours
- •For bacteremia, blood cultures should be repeated at 48-72 hours to assess clearance
- •Once-daily dosing is established from the start — no loading dose needed
- •Mild GI effects are common initially and usually transient
What's next
- →Continue daily IV dosing per indicated schedule
- →Repeat blood cultures at 48-72 hours for bacteremia
- →First CPK check at day 3-7
- →Assess clinical response (fever, WBC, hemodynamics) at 48-72 hours
Days 3-14 (active treatment)
What you might notice
- •Clinical improvement: defervescence, resolving signs of infection
- •Blood culture clearance expected by day 3-5 for susceptible organisms
- •CPK may show mild elevation — usually asymptomatic
- •For cSSSI: visible improvement in skin infection by day 3-4
What's normal
- •cSSSI treatment typically completed in 7-14 days
- •Bacteremia clearance should occur by day 3-5; if persistent, reassess
- •Mild CPK elevation is common and not necessarily an indication to stop
- •Once-daily dosing may allow OPAT transition for clinically stable patients
What's next
- →Continue weekly CPK monitoring throughout treatment
- →For cSSSI: complete 7-14 day course as clinically indicated
- →For bacteremia: continue until 2 weeks after first negative blood culture
- →For endocarditis: plan for 4-6 week total treatment course
Week 2-6 (extended treatment/completion)
What you might notice
- •Infection resolving or resolved depending on indication
- •Endocarditis patients: continued improvement on echocardiographic follow-up
- •CPK typically returns to normal within 1 week of completing therapy
- •Overall recovery and return to baseline function
What's normal
- •Extended courses (4-6 weeks) are standard for endocarditis and osteoarticular infections
- •OPAT allows patients to receive remaining treatment at home
- •CPK should be monitored weekly through end of therapy
- •Post-treatment relapse surveillance is recommended for endocarditis
What's next
- →Complete the full treatment course per infectious disease guidance
- →Final CPK check at end of treatment to confirm normalization
- →Resume statins if held during daptomycin therapy (after 1 week off daptomycin)
- →Follow-up blood cultures and clinical assessment post-treatment
Signs it's working · Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Daptomycin over time
- ✓Reduction in symptom frequency or severity
Signs it's working · General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key research
07 · Questions
Frequently asked
Why can't daptomycin be used for pneumonia?+
Daptomycin is completely inactivated by pulmonary surfactant — the phospholipid-rich substance that lines the alveoli in the lungs. Surfactant phosphatidylcholine binds daptomycin's lipid tail and sequesters the drug, preventing it from interacting with bacterial membranes. A clinical trial comparing daptomycin to ceftriaxone for community-acquired pneumonia (CAP) showed daptomycin was significantly inferior, confirming that it should never be used for any lung infection. This is the single most important clinical limitation to remember.
How was daptomycin 'rescued' from failure?+
Eli Lilly discovered daptomycin in the 1980s from Streptomyces roseosporus but abandoned it due to skeletal muscle toxicity at the twice-daily dosing used in initial trials. Cubist Pharmaceuticals acquired the rights and made the crucial discovery that once-daily dosing maintained the same antimicrobial efficacy while dramatically reducing myotoxicity. The 24-hour drug-free interval between daily doses allows skeletal muscle cells to recover from daptomycin's phospholipid membrane effects. This pharmacological insight transformed daptomycin from a failed drug candidate into one of the most important antibiotics of the 21st century.
What is the 'seesaw effect' with ceftaroline?+
The seesaw effect describes an inverse relationship between daptomycin and beta-lactam resistance in S. aureus: mutations that increase daptomycin MIC (such as changes in membrane phospholipid composition) simultaneously increase susceptibility to beta-lactams. This means adding a beta-lactam like ceftaroline to daptomycin therapy can restore or enhance activity against daptomycin-resistant or daptomycin-nonsusceptible MRSA. The daptomycin + ceftaroline combination has become a standard salvage regimen for persistent MRSA bacteremia.
Why is CPK monitoring required?+
Daptomycin interacts with skeletal muscle cell membranes (which contain phosphatidylglycerol-like phospholipids) similarly to how it disrupts bacterial membranes, though at a much lower degree at therapeutic concentrations. This can cause skeletal muscle fiber damage, releasing creatine phosphokinase (CPK) into the blood. CPK monitoring weekly allows early detection of myotoxicity before it progresses to symptomatic myopathy or rhabdomyolysis. CPK >5x ULN with muscle symptoms or >10x ULN without symptoms is the typical threshold for discontinuation.
How does daptomycin compare to vancomycin for MRSA?+
Both are first-line options for serious MRSA infections, but they have important differences. Daptomycin offers several advantages: faster bactericidal killing, once-daily dosing (vs vancomycin's twice-daily with trough monitoring), no need for therapeutic drug monitoring in most patients, and activity against vancomycin-intermediate (VISA) and some vancomycin-resistant strains. Vancomycin's advantages include broader evidence base, IV-to-oral step-down option, ability to treat pneumonia, and no restriction against lung infections. For MRSA bacteremia specifically, several comparative studies suggest daptomycin may achieve faster bloodstream clearance.
Is daptomycin effective against biofilms?+
Yes, daptomycin maintains bactericidal activity against biofilm-embedded and stationary-phase bacteria, unlike many conventional antibiotics that require actively growing cells. This makes daptomycin particularly valuable for prosthetic joint infections, intravascular device infections, and endocarditis vegetations where biofilm-tolerant bacterial subpopulations survive standard antibiotic therapy. Combination with rifampicin further enhances anti-biofilm activity, as rifampicin penetrates the biofilm matrix while daptomycin provides the membrane-targeting kill.
08 · Further reading
History & related research
History · since 1987
The antibiotic Eli Lilly threw away—rescued by one determined doctor.
Daptomycin is an antibiotic that kills superbugs like MRSA and VRE by punching holes in their cell walls. It was discovered in 1987 but abandoned by Eli Lilly due to toxicity.
Read the full history of Daptomycin